Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael J Jackson

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
The European Journal of Neuroscience|March 25, 2005
A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosetsMahmoud M Iravani, Emilie Syed, Michael J Jackson, et al.
Pharmacology, Biochemistry, and Behavior|December 8, 2004
Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosetsMichael J Jackson, Ghassan Al-Barghouthy, Ronald K B Pearce, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 3, 2002
The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosetsRonald K B Pearce, Lance A Smith, Michael J Jackson, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 19, 2004
Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primatesLance A Smith, Michael J Jackson, Ghassan Al-Barghouthy, et al.
Phytotherapy Research : PTR|January 26, 2018
The effect of Banisteriopsis caapi (B. caapi) on the motor deficits in the MPTP-treated common marmoset model of Parkinson's diseaseRia Fisher, Louise Lincoln, Michael J Jackson, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 3, 2016
Oral r-(-)-11-o-valeryl-n-n-propylnoraporphine reverses motor deficits in mptp-treated marmosetsLouise Lincoln, Ria Fisher, Michael J Jackson, et al.
Neuropharmacology|February 15, 2020
The selective 5-HT<sub>1A</sub> receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosetsRia Fisher, Atsuko Hikima, Rebecca Morris, et al.
Clinical Neuropharmacology|June 15, 2006
Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primatesLance A Smith, Michael J Jackson, Louisa Johnston, et al.
Experimental Neurology|October 16, 2007
The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primatesMohammed Zubair, Michael J Jackson, Kayhan Tayarani-Binazir, et al.
The European Journal of Neuroscience|September 30, 2005
Unilateral pallidotomy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets exhibiting levodopa-induced dyskinesiaMahmoud M Iravani, Sergio Costa, Ghassan Al-Bargouthy, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
The European Journal of Neuroscience|March 25, 2005
A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosetsMahmoud M Iravani, Emilie Syed, Michael J Jackson, et al.
Pharmacology, Biochemistry, and Behavior|December 8, 2004
Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosetsMichael J Jackson, Ghassan Al-Barghouthy, Ronald K B Pearce, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 3, 2002
The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosetsRonald K B Pearce, Lance A Smith, Michael J Jackson, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 19, 2004
Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primatesLance A Smith, Michael J Jackson, Ghassan Al-Barghouthy, et al.
Phytotherapy Research : PTR|January 26, 2018
The effect of Banisteriopsis caapi (B. caapi) on the motor deficits in the MPTP-treated common marmoset model of Parkinson's diseaseRia Fisher, Louise Lincoln, Michael J Jackson, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 3, 2016
Oral r-(-)-11-o-valeryl-n-n-propylnoraporphine reverses motor deficits in mptp-treated marmosetsLouise Lincoln, Ria Fisher, Michael J Jackson, et al.
Neuropharmacology|February 15, 2020
The selective 5-HT<sub>1A</sub> receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosetsRia Fisher, Atsuko Hikima, Rebecca Morris, et al.
Clinical Neuropharmacology|June 15, 2006
Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primatesLance A Smith, Michael J Jackson, Louisa Johnston, et al.
Experimental Neurology|October 16, 2007
The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primatesMohammed Zubair, Michael J Jackson, Kayhan Tayarani-Binazir, et al.
The European Journal of Neuroscience|September 30, 2005
Unilateral pallidotomy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets exhibiting levodopa-induced dyskinesiaMahmoud M Iravani, Sergio Costa, Ghassan Al-Bargouthy, et al.
Pageof 4